BIOMAT Database Logo BIOMAT Database Logo

Serum glial fibrillary acidic protein as a biomarker of brain injury in premature neonates. 2022

Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Department of Midwifery, University of West Attica, Athens, Greece.

Neonatal brain injury is a serious adverse outcome of prematurity. Early detection of high risk premature neonates to develop neonatal brain injury is not currently feasible. The predictive value of many biomarkers has been tested, but none is used currently in clinical practice. The purpose of this study was to determine the levels and predictive value of serum glial fibrillary acidic protein (GFAP) in a prospective longitudinal case-control study during the first three days of life in premature neonates (<34 weeks of gestation) that later developed either intraventricular hemorrhage or periventricular leukomalacia. Each case (n=29) was matched according to birth weight and gestational age to one neonate with normal head ultrasound scans. No significant difference on GFAP levels was observed between the groups. Nevertheless, neonates with brain injury presented more frequently GFAP levels above the lowest detection limit (0.056 ng/ml) and this trend was significantly different during all days. The effectiveness of GFAP as an early biomarker of neonatal brain injury in premature neonates seems to be limited.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001930 Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. Brain Lacerations,Acute Brain Injuries,Brain Injuries, Acute,Brain Injuries, Focal,Focal Brain Injuries,Injuries, Acute Brain,Injuries, Brain,Acute Brain Injury,Brain Injury,Brain Injury, Acute,Brain Injury, Focal,Brain Laceration,Focal Brain Injury,Injuries, Focal Brain,Injury, Acute Brain,Injury, Brain,Injury, Focal Brain,Laceration, Brain,Lacerations, Brain
D005904 Glial Fibrillary Acidic Protein An intermediate filament protein found only in glial cells or cells of glial origin. MW 51,000. Glial Intermediate Filament Protein,Astroprotein,GFA-Protein,Glial Fibrillary Acid Protein,GFA Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Glial fibrillary acidic protein as a biomarker for brain injury in neonatal CHD.
October 2016, Cardiology in the young,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Glial fibrillary acidic protein: a promising biomarker in pediatric brain injury.
September 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation.
September 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Glial fibrillary acidic protein as a biomarker for periventricular white matter injury.
July 2013, American journal of obstetrics and gynecology,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study.
October 2015, Critical care (London, England),
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Serum glial fibrillary acidic protein as a diagnostic biomarker in dogs with progressive myelomalacia.
July 2013, The Journal of veterinary medical science,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
May 2021, Annals of neurology,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma.
November 2004, The Journal of trauma,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Serum Glial Fibrillary Acidic Protein Predicts Tissue Glial Fibrillary Acidic Protein Break-Down Products and Therapeutic Efficacy after Penetrating Ballistic-Like Brain Injury.
January 2016, Journal of neurotrauma,
Dimitra Metallinou, and Grigorios Karampas, and Georgia Nyktari, and Nicoletta Iacovidou, and Katerina Lykeridou, and Demetrios Rizos
Serum glial fibrillary acidic protein as a predictive biomarker of neurological outcome after cardiac arrest.
July 2009, Resuscitation,
Copied contents to your clipboard!